Page last updated: 2024-12-05

tempidon

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,2,6,6-tetramethyl-4-piperidinone: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID13220
CHEMBL ID117614
CHEBI ID177813
SCHEMBL ID38953
MeSH IDM0042806

Synonyms (79)

Synonym
AC-2702
trojacetonoaminy
2k4430s3xp ,
unii-2k4430s3xp
ec 212-554-2
5-21-06-00538 (beilstein handbook reference)
to0127900
CHEBI:177813
4-piperidinone, 2,2,6,6-tetramethyl-
triacetonamine
vincubina
nsc-16579
triacetonamin
2,6,6-tetramethyl-4-piperidone
nsc16579
2,6,6-tetramethyl-4-oxopiperidine
826-36-8
vincubine
2,6,6-tetramethyl-4-piperidinone
triacetone amine
2,2,6,6-tetramethyl-4-piperidone
2,2,6,6-tetramethylpiperidin-4-one
OPREA1_386573
brn 0112665
2,2,6,6-tetramethyl-4-piperidinone
4-oxo-2,2,6,6-tetramethyl-4-piperidone
einecs 212-554-2
2,2,6,6-tetramethylpiperidone-4-toluene-p- sulfonate
tempidon
tmpone
2,2,6,6-tetramethylpiperidone
2,2,6,6-tetramethylpiperidinone
4-oxo-2,2,6,6-tetramethylpiperidine
4-piperidone, 2,2,6,6-tetramethyl-
trojacetonoaminy [polish]
2,2,6,6-tetramethyl-4-oxopiperidine
nsc 16579
2,2,6,6-tetramethyl-4-piperidone, 95%
SR-01000634150-1
STK256617
CHEMBL117614
inchi=1/c9h17no/c1-8(2)5-7(11)6-9(3,4)10-8/h10h,5-6h2,1-4h3
jwuxjyzvkzkltj-uhfffaoysa-
T1424
odoratine
AKOS000120903
NCGC00248182-01
2,2,6,6-tetramethyl-piperidin-4-one
NCGC00254720-01
dtxsid4041527 ,
cas-826-36-8
dtxcid2021527
tox21_300816
triacetoneamine
tetramethylpiperidinone
CCG-44306
FT-0609128
ikh-19
AB00375601-03
SCHEMBL38953
2,2,6,6-teramethyl-4-piperidone
W-104169
ikh 196
STR06804
4-oxo-2,2,6,6-tetramethylpiperidine (d17, 15n)
F8889-5387
mfcd00005975
odoratin?
2,2,6,6-tetramethyl-g-piperidone
2,2,6, 6-tetramethyl-4-piperidinone
Z1250100692
CS-0016419
Q6120732
HY-N1131
SB74533
P19976
NCGC00248182-02
S4859
EN300-18105
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
piperidones
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
estrogen nuclear receptor alphaHomo sapiens (human)Potency0.01220.000229.305416,493.5996AID743069
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID781327pKa (acid-base dissociation constant) as determined by Morgenthaler ref: ChemMedChem 20072014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID216890Mean surviving fraction of V79 cells following a 1-h exposure to H2O2.1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Studies of structure-activity relationship of nitroxide free radicals and their precursors as modifiers against oxidative damage.
AID216900Mean surviving fraction of V79 cells following a 12-Gy dose of radiation.1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Studies of structure-activity relationship of nitroxide free radicals and their precursors as modifiers against oxidative damage.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (44)

TimeframeStudies, This Drug (%)All Drugs %
pre-199011 (25.00)18.7374
1990's12 (27.27)18.2507
2000's11 (25.00)29.6817
2010's6 (13.64)24.3611
2020's4 (9.09)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.36

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.36 (24.57)
Research Supply Index3.83 (2.92)
Research Growth Index4.55 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.36)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other45 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]